{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:07:19Z","timestamp":1648620439594},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"Merck Sharp & Dohme (MSD) Greece."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n                        Background Metformin, in the absence of contraindications or\n                        intolerance, is recommended as first-line treatment for patients with type 2\n                        diabetes mellitus (T2DM). This observational, retrospective study assessed\n                        the real-world adequacy of glycaemic control in Greek patients with T2DM\n                        initiating metformin monotherapy at maximum tolerated dose.<\/jats:p><jats:p>\n                        Methods Included patients received metformin monotherapy for\n                        \u226524 months; relevant patient data were collected immediately prior\n                        to metformin initiation (baseline) and at other prespecified time points.\n                        The primary objective was to report, after 9 months of metformin treatment,\n                        the percentage of patients with baseline glycated haemoglobin\n                            (HbA1c) levels \u22656.5%\n                        (\u226548\u2009mmol\/mol) achieving\n                        HbA1c&lt;6.5%. Secondary objectives included the\n                        assessment of time spent with poor glycaemic control and time to treatment\n                        intensification. A sensitivity analysis assessed the percentage of patients\n                        with baseline HbA1c\u22657%\n                        (\u226553\u2009mmol\/mol) achieving\n                        HbA1c&lt;7%\n                        (&lt;53\u2009mmol\/mol).<\/jats:p><jats:p>\n                        Results Of the enrolled patients (N=316), 247 had baseline\n                            HbA1c \u22656.5%; following 9 months on metformin,\n                        90 (36.4%) patients achieved HbA1c&lt;6.5%\n                        (mean HbA1c change\u22121.3%\n                        [\u221214\u2009mmol\/mol]). Median time of exposure to\n                            HbA1c \u22656.5% was 23.4 months and time to\n                        treatment intensification was 28.0 months. The sensitivity analysis revealed\n                        that the proportion of patients achieving\n                        HbA1c&lt;7.0% was 50% (mean\n                        HbA1cpy for up to 24 months. Addressing clinical inertia could\n                        improve disease outcomes and, possibly, economic burden.<\/jats:p>","DOI":"10.1055\/a-0824-6607","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T01:06:41Z","timestamp":1548205601000},"page":"224-230","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Adequacy of Glycaemic Control in Treatment-Na\u00efve\n                    Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin\n                    Monotherapy at the Maximum Tolerated Dose: The Reload Study"],"prefix":"10.1055","volume":"128","author":[{"given":"Vasilis","family":"Tsimihodimos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of\n                    Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Bargiota","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, University of\n                    Thessaly School of Medicine, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil M.","family":"Pagkalos","sequence":"additional","affiliation":[{"name":"Private Hospital Thermi Clinic, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Manes","sequence":"additional","affiliation":[{"name":"Diabetes Center, Papageorgiou General Hospital, Thessaloniki,\n                    Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aggelos","family":"Papas","sequence":"additional","affiliation":[{"name":"Diabetes Center, Venizelio General Hospital Heraklion, Crete,\n                    Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Karamousouli","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme (MSD), Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Voss","sequence":"additional","affiliation":[{"name":"MSD RBSC, Lindenplatz 1, Haar Deutschland, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses S","family":"Elisaf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of\n                    Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,1,22]]},"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0824-6607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T22:37:08Z","timestamp":1586212628000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0824-6607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":0,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2020,4,6]]},"published-print":{"date-parts":[[2020,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0824-6607","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]}}}